The global pharmaceutical CRO market size accounted for USD 44.58 billion in 2024, grew to USD 47.89 billion in 2025 and is predicted to surpass around USD 91.20 billion by 2034, representing a solid CAGR of 7.42% between 2024 and 2034. The Asia Pacific pharmaceutical CRO market size is evaluated at USD 20.95 billion in 2024 and is expected to grow at a solid CAGR of 7.52% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmaceutical CRO Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmaceutical CRO Market, by Type, 2024-2034
8.1.1. Drug Discovery
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Pre-Clinical
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Clinical
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Pharmaceutical CRO Market, by Molecule Type, 2024-2034
9.1.1. Small Molecules
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Large Molecules
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Pharmaceutical CRO Market, by Service, 2024-2034
10.1.1. Project Management/Clinical Supply Management
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Data Management
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Regulatory/Medical Affairs
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Medical Writing
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Clinical Monitoring
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Quality Management/ Assurance
10.1.6.1. Market Revenue and Forecast (2021-2034)
10.1.7. Biostatistics
10.1.7.1. Market Revenue and Forecast (2021-2034)
10.1.8. Investigator Payments
10.1.8.1. Market Revenue and Forecast (2021-2034)
10.1.9. Laboratory
10.1.9.1. Market Revenue and Forecast (2021-2034)
10.1.10. Patient And Site Recruitment
10.1.10.1. Market Revenue and Forecast (2021-2034)
10.1.11. Technology
10.1.11.1. Market Revenue and Forecast (2021-2034)
10.1.12. Others
10.1.12.1. Market Revenue and Forecast (2021-2034)
11.1. Pharmaceutical CRO Market, by Therapeutic Areas, 2024-2034
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Cns Disorders
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Infectious Diseases
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Immunological Disorders
11.1.4.1. Market Revenue and Forecast (2021-2034)
11.1.5. Cardiovascular Disease
11.1.5.1. Market Revenue and Forecast (2021-2034)
11.1.6. Respiratory Diseases
11.1.6.1. Market Revenue and Forecast (2021-2034)
11.1.7. Diabetes
11.1.7.1. Market Revenue and Forecast (2021-2034)
11.1.8. Ophthalmology
11.1.8.1. Market Revenue and Forecast (2021-2034)
11.1.9. Pain Management
11.1.9.1. Market Revenue and Forecast (2021-2034)
11.1.10. Others
11.1.10.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2021-2034)
12.1.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.1.3. Market Revenue and Forecast, by Service (2021-2034)
12.1.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Service (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Service (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.2.3. Market Revenue and Forecast, by Service (2021-2034)
12.2.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Service (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Service (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Service (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Service (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.3.3. Market Revenue and Forecast, by Service (2021-2034)
12.3.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Service (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Service (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Service (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Service (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.4.3. Market Revenue and Forecast, by Service (2021-2034)
12.4.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Service (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Service (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Service (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Service (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.5.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.5.3. Market Revenue and Forecast, by Service (2021-2034)
12.5.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Service (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Molecule Type (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Service (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Therapeutic Areas (2021-2034)
13.1. Thermo Fisher Scientific Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Medpace
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. IQVIA
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. CTI Clinical Trial & Consulting
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Parexel International (MA) Corporation.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. ICON plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Laboratory Corporation of America Holdings
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. WuXi AppTec
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Veeda Clinical Research
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample